Answers are grounded in this paper and cite their sources.
INTRODUCTION: Tobacco use remains a cause of avoidable disease and economic loss in Türkiye. Evidence is limited on the consequences of generation-based sales restrictions compared with conventional tobacco control. METHODS: We developed a dynamic open-cohort state-transition model of Türkiye's population aged ≥15 years. Over 50 annual cycles, baseline smoking was compared with enhanced cessation, stronger prevention, and a fully effective generation-based sales ban. Outcomes included smoking prevalence, disease cases and deaths, life-years, disability-adjusted life years (DALYs), healthcare savings, tobacco tax revenue, productivity, and household cigarette expenditure. Monetary outcomes were expressed in 2025 international dollars; uncertainty was assessed using 1,000 Monte Carlo simulations. RESULTS: By year 50, smoking prevalence was 30.4% under baseline, 27.5% with enhanced cessation, 24.2% with stronger prevention, and 5.6% under the generation-based sales ban. The ban prevented 8.45 million disease cases and 1.87 million disease-specific deaths and generated 10.48 million discounted life-years and 18.26 million discounted DALYs. Discounted healthcare savings were 3.64, 7.39, and 13.40 billion 2025 international dollars for cessation, prevention, and the ban; corresponding societal gains were 11.37, 27.55, and 61.85 billion. All policies reduced tobacco tax receipts, producing negative net fiscal effects. CONCLUSIONS: A fully effective generation-based sales ban produced the largest health and societal gains. It should complement cessation support and conventional tobacco control, with planning for declining tobacco tax revenue.
No takes yet. Share an insight, caveat, or question.
Kar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: